Sandbox vidit: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 6: Line 6:
{{familytree | | | B01 | | | | | | B02 | | | | | | |B01=Unstable |B02=Stable }}
{{familytree | | | B01 | | | | | | B02 | | | | | | |B01=Unstable |B02=Stable }}
{{familytree | | | |!| | | | | | | |!| | | | | | | | }}
{{familytree | | | |!| | | | | | | |!| | | | | | | | }}
{{familytree | | | C01 | | | | | | C02 | | | | | | |C01=<div style="float: left; text-align: left; width:28em; padding:1em;">❑ Look for the presence of any of these: <br>
{{familytree | | | C01 | | | | | | C02 | | | | | | |C01=<div style="float: left; text-align: left; width:28em; ">❑ Look for the presence of any of these: <br>
:❑ Chronic heart failure  
:❑ Chronic heart failure  
:❑ Hypotension
:❑ Hypotension
Line 14: Line 14:
<tr><td>▸ '''''Conversion'''''</td><td> ▸ '''''DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])'''''</td></tr>
<tr><td>▸ '''''Conversion'''''</td><td> ▸ '''''DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])'''''</td></tr>
<tr><td>▸ '''''Rate control'''''</td><td>▸ '''''[[Beta blockers]] ([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])'''''<br> or <br>▸ '''''[[Verapamil]] or [[diltiazem]] ([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])'''''<br> or <br>▸ '''''[[Digitalis]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])'''''<br> or <br>▸ '''''[[Amiodarone]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])'''''</td></tr>
<tr><td>▸ '''''Rate control'''''</td><td>▸ '''''[[Beta blockers]] ([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])'''''<br> or <br>▸ '''''[[Verapamil]] or [[diltiazem]] ([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])'''''<br> or <br>▸ '''''[[Digitalis]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])'''''<br> or <br>▸ '''''[[Amiodarone]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])'''''</td></tr>
</table></div>|C02=<div style="float: left; text-align: left; width:28em; padding:1em;"> ❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours <br> Rate control therapy as shown in table below:
</table></div>|C02=<div style="float: left; text-align: left; width:28em; "> ❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours <br> Rate control therapy as shown in table below:


<table class="wikitable">
<table class="wikitable">
Line 20: Line 20:
</table> </div> }}
</table> </div> }}
{{familytree | | | |!| | | | | | | |!| | | | | | | | | }}
{{familytree | | | |!| | | | | | | |!| | | | | | | | | }}
{{familytree | | | |!| | | | | | | G01 | | | | | | | |G01=<div style="float: left; text-align: left; width:25em; padding:1em;"> ❑ Attempt conversion as shown in table below: <br>
{{familytree | | | |!| | | | | | | G01 | | | | | | | |G01=<div style="float: left; text-align: left; width:25em; "> ❑ Attempt conversion as shown in table below: <br>
<table class="wikitable">
<table class="wikitable">
<tr><td>▸ '''''Conversion'''''</td><td>▸ '''''Atrial or transesophageal pacing ([[ACC AHA guidelines classification scheme|class I, level of evidence A]])'''''<br> or <br>▸ '''''DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])'''''<br> or <br>▸ '''''Ibutilide ([[ACC AHA guidelines classification scheme|class IIa, level of evidence A]])'''''<br> or <br>▸ '''''Flecainide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]])'''''<br> or <br>▸ '''''Propafenone ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]])'''''<br> or <br>▸ '''''Sotalol ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])'''''<br> or <br>▸ '''''Procainamide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]])'''''<br> or <br>▸ '''''Amiodarone ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])''''' </td></tr>
<tr><td>▸ '''''Conversion'''''</td><td>▸ '''''Atrial or transesophageal pacing ([[ACC AHA guidelines classification scheme|class I, level of evidence A]])'''''<br> or <br>▸ '''''DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])'''''<br> or <br>▸ '''''Ibutilide ([[ACC AHA guidelines classification scheme|class IIa, level of evidence A]])'''''<br> or <br>▸ '''''Flecainide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]])'''''<br> or <br>▸ '''''Propafenone ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]])'''''<br> or <br>▸ '''''Sotalol ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])'''''<br> or <br>▸ '''''Procainamide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]])'''''<br> or <br>▸ '''''Amiodarone ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])''''' </td></tr>
</table> </div> }}
</table> </div> }}
{{familytree | | | |`|-|-|-|v|-|-|-|'| | | | | | | | }}
{{familytree | | | |`|-|-|-|v|-|-|-|'| | | | | | | | }}
{{familytree | | | | | | | D01 | | | | | | | | | | |D01=<div style="float: left; text-align: left; padding:1em;"> ❑ Assess need for therapy to prevent recurrence </div> |D02=}}
{{familytree | | | | | | | D01 | | | | | | | | | | |D01=<div style="float: left; text-align: left; "> ❑ Assess need for therapy to prevent recurrence </div> |D02=}}
{{familytree | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | E01 | | | | | | | | | | |E01=<div style="float: left; text-align: left; width:25em; padding:1em;"> ❑ Administer antiarrythmic therapy to prevent recurrences as shown below: <br>
{{familytree | | | | | | | E01 | | | | | | | | | | |E01=<div style="float: left; text-align: left; width:25em; "> ❑ Administer antiarrythmic therapy to prevent recurrences as shown below: <br>


<table class="wikitable">
<table class="wikitable">

Revision as of 15:15, 12 March 2014

Therapeutic Approach

Shown below is an algorithm summarizing the therapeutic approach to atrial flutter.[1]

 
 
 
 
 
 
Atrial flutter
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unstable
 
 
 
 
 
Stable
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Look for the presence of any of these:
❑ Chronic heart failure
❑ Hypotension
❑ Acute myocardial infarction
❑ If present, treat as shown in the table below:
ConversionDC cardioversion (class I, level of evidence C)
Rate controlBeta blockers (class IIa, level of evidence C)
or
Verapamil or diltiazem (class IIa, level of evidence C)
or
Digitalis (class IIb, level of evidence C)
or
Amiodarone (class IIb, level of evidence C)
 
 
 
 
 
❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours
Rate control therapy as shown in table below:
Rate controlBeta blockers (class IIa, level of evidence C)
or
Verapamil or diltiazem (class IIa, level of evidence C)
or
Digitalis (class IIb, level of evidence C)
or
Amiodarone (class IIb, level of evidence C)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Attempt conversion as shown in table below:
ConversionAtrial or transesophageal pacing (class I, level of evidence A)
or
DC cardioversion (class I, level of evidence C)
or
Ibutilide (class IIa, level of evidence A)
or
Flecainide (class IIb, level of evidence A)
or
Propafenone (class IIb, level of evidence A)
or
Sotalol (class IIb, level of evidence C)
or
Procainamide (class IIb, level of evidence A)
or
Amiodarone (class IIb, level of evidence C)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Assess need for therapy to prevent recurrence
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Administer antiarrythmic therapy to prevent recurrences as shown below:
First episode and well-tolerated atrial flutterCardioversion alone (class I, level of evidence B)
or
Catheter ablation (class IIa, level of evidence B)
Recurrent and well-tolerated atrial flutterCatheter ablation(class I, level of evidence B)
or
Dofetilide (class IIa, level of evidence C)
or
Amiodarone (class IIb, level of evidence C)
or
Sotalol
or
Flecainide
or
Quinidine
or
Propafenone
or
Procainamide
or
Disopyramide
Poorly tolerated atrial flutterCatheter ablation (class I, level of evidence B)
Atrial flutter appearing after use of class Ic agents or amiodarone for treatment of AFCatheter ablation (class I, level of evidence B)
or
Stop current drug and use another (class IIa, level of evidence C)
Symptomatic non–CTI-dependent flutter after failed antiarrhythmic drug therapyCatheter ablation (class IIa, level of evidence B)

❑ Consider catheter ablation if antiarrhythmic therapy fails
 
 
 
 
 
 
 
 
 
 
  1. "ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary". Retrieved 15 August 2013.